MEMO TO THE MEDIA
Breast Cancer Incidence in Canada Declines as Hormone Therapy Drops
Quality of Life of Breast Cancer Survivors with Physical Limitations
ORIGINAL ARTICLES
Xinhui Wang, Takuya Osada, Yangyang Wang, Ling Yu, Koichi Sakakura, Akihiro Katayama, James B. McCarthy, Adam Brufsky, Mamatha Chivukula, Thaer Khoury, David S. Hsu, William T. Barry, H. Kim Lyerly, Timothy M. Clay, and Soldano Ferrone CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
MEMO TO THE MEDIA
Adding Topotecan to Standard Treatment for Ovarian Cancer Does Not Improve Progression-Free Survival
JNCI J Natl Cancer Inst (2010) 102(20): NP first published online October 11, 2010 doi:10.1093/jnci/djq437 Extract
REVIEW
Jonathan A. Ewald, Joshua A. Desotelle, George Wilding, and David F. Jarrard
Therapy-Induced Senescence in Cancer JNCI J Natl Cancer Inst (2010) 102(20): 1536-1546 first published online September 21, 2010 doi:10.1093/jnci/djq364 Abstract
ARTICLES
P. Hoskins, I. Vergote, A. Cervantes, D. Tu, G. Stuart, P. Zola, A. Poveda, D. Provencher, D. Katsaros, B. Ojeda, P. Ghatage, R. Grimshaw, A. Casado, L. Elit, C. Mendiola, A. Sugimoto, V. D'Hondt, A. Oza, J. R. Germa, M. Roy, L. Brotto, D. Chen, and E. A. Eisenhauer
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel JNCI J Natl Cancer Inst (2010) 102(20): 1547-1556 first published online October 11, 2010 doi:10.1093/jnci/djq362 Abstract
Lynette Denny, Louise Kuhn, Chih-Chi Hu, Wei-Yann Tsai, and Thomas C. Wright, Jr
Human Papillomavirus–Based Cervical Cancer Prevention: Long-term Results of a Randomized Screening Trial JNCI J Natl Cancer Inst (2010) 102(20): 1557-1567 first published online September 30, 2010 doi:10.1093/jnci/djq342 Abstract
